In this study, investigators will investigate the change of objective measurements of lung functions and exercise capacity in addition to subjective measures of quality of life.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
COPD patients, stages 3-4 according to GOLD guidelines 2016, with post bronchodilator FEV1/FVC \< 70% of predicted and FEV1 \< 50% with exacerbations necessitates hospital admission.
Smokers or Ex-smokers.
Able and willing to provide informed signed consent. Able and understanding the correct use of the bronchial clearing device.
Able to perform effectively spirometry.
Able and willing to receive the management plane as indicated including systemic steroids if seemed necessary.
You may not be if
Other obstructive pulmonary diseases or those do not fulfill the criteria of COPD diagnosis.
Nonsmokers.
Presence of major comorbidity causing organ dysfunction as cardiac (including severe pulmonary hypertension), renal, or liver impairment (not including diabetes, arterial hypertension, or obesity).
Presence of lobar pneumonia.
Suspicion of bronchogenic malignancy.
Any other complication either at admission or during hospital stay as pneumothorax, pulmonary embolism, myocardial infarction, acute coronary syndrome, cerebrovascular accidents, ...
Patients unable or not willing to provide informed signed consent.
Patients unable to use the bronchial clearing device.
Patients unable to perform spirometry.
Patients unable or not willing to comply to the management plan or the study protocol.
Patients receiving regular oral steroids or non-selective beta blockers.
Clareo Health | Oscillating Positive Expiratory Pressure Devices and Acute Exacerbation of Chronic Obstructive Pulmonary Disease
